Roger Stupp, MD

Videos

Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.

Adding TTFields to Chemotherapy to Improves Survival in Glioblastoma

Roger Stupp, MD, professor of oncology, University of Zurich, discusses the EF-14 trial which compared standard of care for glioblastoma plus or minus tumor treating fields with Optune. Median overall survival was 20.8 months for temozolomide plus&nbsp;Optune versus 16.0 months for temozolomide-alone (HR, 0.65; 95% CI, 0.54-0.79;

Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields.&nbsp;

Roger Stupp, MD | Authors

Articles

Adding TTFields to Chemotherapy to Improves Survival in Glioblastoma

Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer